Agenus/$AGEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Agenus
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
Ticker
$AGEN
Sector
Primary listing
Employees
81
Headquarters
Website
Agenus Metrics
BasicAdvanced
$124M
-
-$0.00
1.67
-
Price and volume
Market cap
$124M
Beta
1.67
52-week high
$7.34
52-week low
$1.38
Average daily volume
469K
Financial strength
Current ratio
0.412
Quick ratio
0.031
Long term debt to equity
-3.644
Total debt to equity
-20.124
Interest coverage (TTM)
-0.37%
Profitability
EBITDA (TTM)
-10.557
Gross margin (TTM)
96.52%
Net profit margin (TTM)
0.10%
Operating margin (TTM)
-18.00%
Revenue per employee (TTM)
$1,410,000
Management effectiveness
Return on assets (TTM)
-5.67%
Return on equity (TTM)
1.06%
Valuation
Price to revenue (TTM)
0.844
Price to book
-0.42
Price to tangible book (TTM)
-0.38
Price to free cash flow (TTM)
-1.248
Free cash flow yield (TTM)
-80.14%
Free cash flow per share (TTM)
-2.596
Growth
Revenue change (TTM)
10.37%
Earnings per share change (TTM)
-99.97%
3-year revenue growth (CAGR)
5.22%
10-year revenue growth (CAGR)
16.49%
3-year earnings per share growth (CAGR)
-93.99%
10-year earnings per share growth (CAGR)
-58.54%
What the Analysts think about Agenus
Analyst ratings (Buy, Hold, Sell) for Agenus stock.
Agenus Financial Performance
Revenues and expenses
Agenus Earnings Performance
Company profitability
Agenus News
AllArticlesVideos
Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access
Business Wire·4 days ago
Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
Business Wire·2 weeks ago
Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Agenus stock?
Agenus (AGEN) has a market cap of $124M as of March 31, 2026.
What is the P/E ratio for Agenus stock?
The price to earnings (P/E) ratio for Agenus (AGEN) stock is 0 as of March 31, 2026.
Does Agenus stock pay dividends?
No, Agenus (AGEN) stock does not pay dividends to its shareholders as of March 31, 2026.
When is the next Agenus dividend payment date?
Agenus (AGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Agenus?
Agenus (AGEN) has a beta rating of 1.67. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.